RxDoctor Payments Data

Renee Coughlin, MD

Internal Medicine · Augusta, GANPI 1508832338

Payments from drug & device makers

$14,631in general payments, 2019–2025

Across 982 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • GSK$1K
  • Sanofi-aventis U.S. LLC$864
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$14,587100%
  • Education$440%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,631 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$66,570
Medicare patients
236
Services billed
857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$148,108
MounjaroTirzepatide102$141,702
EliquisApixaban97$96,987
JardianceEmpagliflozin90$80,930
JanuviaSitagliptin Phosphate71$75,489
FarxigaDapagliflozin Propanediol59$53,760
LinzessLinaclotide46$38,205
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$34,294
MyrbetriqMirabegron41$29,238
XareltoRivaroxaban13$22,773
RybelsusSemaglutide18$19,056
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$18,614
TrulicityDulaglutide11$13,827
Tresiba Flextouch U-100Insulin Degludec28$13,074
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$9,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,556$167,164122 claims
Lilly USA, LLCMounjaro, Trulicity$1,220$155,529113 claims
PfizerEliquis$617$96,98797 claims
Boehringer IngelheimJardiance, Spiriva Respimat$828$87,881103 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,533$78,495108 claims
MerckJanuvia$230$75,48971 claims
AbbVieLinzess$1,864$38,20546 claims
GSKTrelegy Ellipta$1,098$34,29437 claims
Astellas Pharma US IncMyrbetriq$161$29,23841 claims
Johnson & JohnsonXarelto$54$22,77313 claims
BayerKerendia$432$7,59912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →